NCT06866782 European Registry of Next Generation Imaging in Advanced Prostate Cancer
| NCT ID | NCT06866782 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundacio Puigvert |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2024-09-17 |
| Primary Completion | 2025-12-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2024-09-17 with a primary completion date of 2025-12-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging. Men aged 18 or older with histologically confirmed prostate cancer are eligible to participate in the study if they require imaging to assess potential metastases, either at diagnosis or after relapse and sign a consent form. Patients will receive standard care with no experimental treatments. Imaging and treatment decisions will follow routine clinical practice. Data will be collected from medical records and analysed for research. This study will help doctors understand when NGI should be used, how it affects treatment decisions, and its impact on patient outcomes.
Eligibility Criteria
Inclusion Criteria: 1. Adult male patients (≥18 years with no upper age limit). 2. Histologically proven prostate cancer. 3. Patients who require imaging exploration (conventional, Next-Generation Imaging (NGI), or their combination) at high risk for harbouring metastatic deposits at the hormone-sensitive stage, either at the diagnostic workout of a "naïve" patient or at biochemical relapse/progression after local treatment. 4. Patients who authorize their participation in the study by signing a written informed consent form (ICF). Exclusion Criteria: 1. Patients participating in other interventional or non-interventional study which requires NGI as a triage test for metastatic assessment. 2. Patients with evidence of any other clinically significant disease or condition which in the opinion of the investigator discourages their participation in the study. 3. Patients who will not be able to complete the study.
Contact & Investigator
Francesco Sanguedolce, MD, PhD
STUDY CHAIR
Fundació Puigvert
Frequently Asked Questions
Who can join the NCT06866782 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06866782 currently recruiting?
Yes, NCT06866782 is actively recruiting participants. Contact the research team at fsanguedol@fundacio-puigvert.es for enrollment information.
Where is the NCT06866782 trial being conducted?
This trial is being conducted at Leuven, Belgium, Lille, France, Lyon, France, Paris, France and 11 additional locations.
Who is sponsoring the NCT06866782 clinical trial?
NCT06866782 is sponsored by Fundacio Puigvert. The principal investigator is Francesco Sanguedolce, MD, PhD at Fundació Puigvert. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.